- 中国精品科技期刊
- 中国高校百佳科技期刊
- 中国中文核心期刊
- 中国科学引文数据库核心期刊
| Citation: |
YAN Xi, PAN Yunan, WANG Kaili, et al. Optimization of prescription process of lifitegrast eye drops and evaluation of its efficacy for dry eye disease[J]. J China Pharm Univ, 2024, 55(2): 209 − 216. DOI: 10.11665/j.issn.1000-5048.2023051701
|
In order to develop a more effective drug for dry eye disease, the preparation of lifitegrast eye drops was carried out, and the safety and efficacy of lifitegrast eye drops in vitro and in vivo were investigated. First the method for the determination of lifitegrast content was established, and then the composition and preparation process of the preparation were determined by literature review and single factor experiment. Finally, the safety of lifitegrast eye drops was evaluated by Draize eye irritation test and HE staining, and the therapeutic efficacy was evaluated by Schirmer test and ELISA test. The results showed that the final prescription of lifitegrast eye drops consisted of 5% lifitegrast, 0.4% sodium chloride, 0.3%−0.4% anhydrous disodium hydrogen phosphate, 0.3% sodium thiosulfate pentahydrate and 0.3% sodium hydroxide. The appearance of lifitegrast eye drops was transparent and slightly brownish yellow solution, the pH was7.75±0.05, the osmotic pressure was in the range of 200−330 mOsmol/kg and it had good stability at 60℃ for 3 months. There was no significant difference in irritation study compared with normal saline. Schirmer test showed that tear secretion was increased and the expression of inflammatory factors IL-6, IL-1β and TNF-α in tears were significantly decreased after treatment with lifitegrast eye drops and compared to the commercially available emulsion cyclosporine eye drops, it takes effect faster. The above results indicate that lifitegrast eye drops are simple to prepare and stable, which is a better choice for the rapid treatment of dry eye disease.
| [1] |
Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report[J]. Ocul Surf, 2017, 15(3): 334-365. doi: 10.1016/j.jtos.2017.05.003
|
| [2] |
Ling JW, Chan BCL, Tsang MSM, et al. Current advances in mechanisms and treatment of dry eye disease: toward anti-inflammatory and immunomodulatory therapy and traditional Chinese medicine[J]. Front Med, 2022, 8: 815075. doi: 10.3389/fmed.2021.815075
|
| [3] |
Fang M, Wang DG, Liu PQ. Advances in drug use for dry eye disease[J]. World Clin Drug(世界临床药物), 2022, 43(05): 620-727.
|
| [4] |
Wolffsohn JS, Huarte ST, Jones L, et al. Clinical practice patterns in the management of dry eye disease: a TFOS international survey[J]. Ocul Surf, 2021, 21: 78-86. doi: 10.1016/j.jtos.2021.04.011
|
| [5] |
Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report[J]. Ocul Surf, 2017, 15(3): 575-628. doi: 10.1016/j.jtos.2017.05.006
|
| [6] |
Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease[J]. J Ocul Pharmacol Ther, 2011, 27(1): 23-27. doi: 10.1089/jop.2010.0085
|
| [7] |
He H, Xiao QG. Recent advances of non-steroidal anti-inflammatory drugs in treatment of dry eye[J]. Int J Ophthalmol (国际眼科杂志), 2011, 11(7): 1182-1184.
|
| [8] |
Chan CC, Prokopich CL. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: overview of clinical trial program[J]. J Pharm Pharm Sci, 2019, 22(1): 49-56.
|
| [9] |
Shen Lee B, Toyos M, Karpecki P, et al. Selective pharmacologic therapies for dry eye disease treatment: efficacy, tolerability, and safety data review from preclinical studies and pivotal trials[J]. Ophthalmol Ther, 2022, 11(4): 1333-1369. doi: 10.1007/s40123-022-00516-9
|
| [10] |
Godin MR, Gupta PK. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy[J]. Clin Ophthalmol, 2017, 11: 951-957. doi: 10.2147/OPTH.S117188
|
| [11] |
Zheng F, Wang YM, Zhang Q, et al. Lifitegrast: a novel inhibitor of integrin for dry eye disease[J]. Drug Eval Res (药物评价研究), 2017, 40(6): 880-884.
|
| [12] |
Li JX, Tsai YY, Lai CT, et al. Lifitegrast ophthalmic solution 5% is a safe and efficient eyedrop for dry eye disease: a systematic review and meta-analysis[J]. J Clin Med, 2022, 11(17): 5014. doi: 10.3390/jcm11175014
|
| [13] |
Hovanesian JA, Nichols KK, Jackson M, et al. Real-world experience with lifitegrast ophthalmic solution (Xiidra®) in the US and Canada: retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease[J]. Clin Ophthalmol, 2021, 15: 1041-1054. doi: 10.2147/OPTH.S296510
|
| [14] |
Pepose JS, Qazi MA, Devries DK. Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity[J]. Clin Ophthalmol, 2019, 13: 571-579. doi: 10.2147/OPTH.S196593
|
| [15] |
Karn PR, Do Kim H, Kang H, et al. Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion[J]. Int J Nanomedicine, 2014, 9: 3791-3800.
|
| [16] |
Sánchez-Ríos A, Correa-Gallegos EY, Medina-Espinoza JM, et al. Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% ophthalmic atropine sulfate[J]. Animal Model Exp Med, 2022, 5(3): 266-273. doi: 10.1002/ame2.12218
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Total visits：297591
DownLoad: